Teniloxazine

Teniloxazine
Clinical data
Routes of
administration		 Oral
ATC code None
Legal status
Legal status
  • ℞ (Prescription only)
Identifiers
Synonyms Y-8894
CAS Number 62473-79-4 N
62473-80-7 (maleate)
PubChem (CID) 119114
ChemSpider 106426 YesY
UNII 95Q6WNP25P YesY
Chemical and physical data
Formula C16H19NO2S
Molar mass 289.393 g/mol
3D model (Jmol) Interactive image
 NYesY (what is this?)  (verify)

Teniloxazine (Lucelan, Metatone), also known as sufoxazine and sulfoxazine, is a drug which is marketed in Japan.[1] Though initially investigated as a neuroprotective and nootropic agent for the treatment of cerebrovascular insufficiency in the 1980s,[2][3][4][5][6][7][8][9] it was ultimately developed and approved as an antidepressant instead.[10] It acts as a potent norepinephrine reuptake inhibitor, with fair selectivity over the serotonin and dopamine transporters, and also behaves as an antagonist at the 5-HT2A receptor.[7][10][11]

See also

References

  1. ↑ C. R Ganellin; D. J Triggle; F.. Macdonald (1997). Dictionary of pharmacological agents. CRC Press. p. 1905. ISBN 978-0-412-46630-4. Retrieved 27 October 2011.
  2. ↑ Anami K, Yamamoto Y, Setoguchi M (February 1985). "[Pharmacological studies on sufoxazine (Y-8894). (I) Effects on experimental amnesia in mice]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 85 (2): 71–7. doi:10.1254/fpj.85.71. PMID 2859238.
  3. ↑ Izumi N, Yasuda H (October 1985). "[Pharmacological studies on sufoxazine (Y-8894). (II). Anti-anoxic effect]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 86 (4): 323–8. doi:10.1254/fpj.86.323. PMID 4085932.
  4. ↑ Usa T, Morimoto Y, Fukuda T, Anami K, Setoguchi M, Maruyama Y (October 1986). "[Pharmacological studies on Y-8894. (III). Its effect on the abnormal electrocorticogram induced by destruction of the internal capsule]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 88 (4): 289–97. doi:10.1254/fpj.88.289. PMID 3491778.
  5. ↑ Yasuda H, Izumi N, Nakanishi M, Anami K, Maruyama Y (November 1986). "[Pharmacological studies on Y-8894. (IV). Ameliorative effect on a cerebral energy metabolism disorder induced by KCN]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 88 (5): 363–7. doi:10.1254/fpj.88.363. PMID 3817653.
  6. ↑ Anami K, Yamamoto Y, Setoguchi M, Maruyama Y (March 1987). "[Pharmacological studies on Y-8894. (V) Effect on learning and memory in intact and experimentally amnesic rats]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 89 (3): 145–53. doi:10.1254/fpj.89.145. PMID 2884174.
  7. 1 2 Setoguchi M, Takehara S, Sakamori M, Anami K, Maruyama Y (July 1987). "[Pharmacological studies on Y-8894 (VI). The effect on monoamine uptake and turnover in mouse brain]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 90 (1): 41–9. doi:10.1254/fpj.90.41. PMID 2443434.
  8. ↑ Yasumatsu H, Yamamoto Y, Takamuku H, et al. (December 1987). "[Pharmacological studies on Y-8894. (VII). Effects on transient cerebral ischemia-induced amnesia in rats]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 90 (6): 321–30. doi:10.1254/fpj.90.321. PMID 3443414.
  9. ↑ Anami K, Setoguchi M, Senoh H (August 1988). "[Pharmacological studies on Y-8894. (VIII). Effects on learning and memory in the radial maze task in mice]". Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica (in Japanese). 92 (2): 113–8. doi:10.1254/fpj.92.113. PMID 3224898.
  10. 1 2 Ogura C, Kishimoto A, Kunimoto N, et al. (May 1987). "Clinical pharmacology of a new antidepressant, Y-8894 in healthy young and elderly volunteers". British Journal of Clinical Pharmacology. 23 (5): 537–43. doi:10.1111/j.1365-2125.1987.tb03089.x. PMC 1386189Freely accessible. PMID 3593624.
  11. ↑ "Therapeutic Agent for Attention-Deficit Hyperactivity Disorder - Google Patents". Retrieved October 27, 2011.
This article is issued from Wikipedia - version of the 9/2/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.